Platelet-stored angiogenesis factors: Clinical monitoring is prone to artifacts

Disease Markers

Volumn 31, Issue 2, 2011, Pages 55-65

  Starlinger, Patrick ^a   Alidzanovic, Lejla ^a   Schauer, Dominic ^a   Brugger, Philipp ^a   Sommerfeldt, Silvia ^a   Kuehrer, Irene ^a   Schoppmann, Sebastian F ^a   Gnant, Michael ^a   Brostjan, Christine ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Angiogenesis factors; cancer; plasma; platelet derived endothelial cell growth factor; platelet factor 4; thrombospondin 1; vascular endothelial growth factor

Indexed keywords

ADENOSINE; CITRIC ACID; DIPYRIDAMOLE; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; THEOPHYLLINE; THROMBOCYTE FACTOR 4; THROMBOSPONDIN 1; VASCULOTROPIN;

ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOLOGICAL PROCEDURES; HEMOLYSIS; HUMAN; MALE; PANCREAS CANCER; PLASMA; PRIORITY JOURNAL; RELIABILITY; TEMPERATURE MEASUREMENT;

EID: 80052690959     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.3233/DMA-2011-0798     Document Type: Article

References (40)

1. M.L.Iruela-Arispeand H.F.Dvorak,Angiogenesis: adynamic balance of stimulators and inhibitors, Thromb Haemost 78 (1997), 672-677. (Pubitemid 27289325)
2. D. Hanahan and J. Folkman, Patterns and emerging mecha-nisms of the angiogenic switch during tumorigenesis, Cell 86 (1996), 353-364. (Pubitemid 26272076)
3. N. Ferrara, Vascular endothelial growth factor, Arterioscler Thromb Vasc Biol 29 (2009), 789-791.
4. R.E. Banks, M.A. Forbes, S.E. Kinsey, A. Stanley, E. Ingham, C. Walters and P.J. Selby, Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: sig-nificance for VEGF measurements and cancer biology, Br J Cancer77 (1998), 956-964. (Pubitemid 28101786)
5. N. Ferrara, VEGF as a therapeutic target in cancer, Oncology 69(Suppl 3) (2005), 11-16. (Pubitemid 41680948)
6. J. Adams, P.J. Carder, S. Downey, M.A. Forbes, K. Mac Len-nan, V. Allgar, S. Kaufman, S. Hallam, R. Bicknell, J.J. Walk-er, F Cairnduff, P.J. Selby, T.J. Perren, M. Lansdown and R.E. Banks, Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen, Cancer Res 60 (2000), 2898-2905. (Pubitemid 30395813)
7. A.O. Kaseb, A. Hanbali, M. Cotant, M.M. Hassan, I. Wollner and P. A. Philip, Vascular endothelial growth factor in the man-agement of hepatocellular carcinoma: a review of literature, Cancer 115 (2009), 4895-4906.
8. N. Murukesh, C. Dive and G.C. Jayson, Biomarkers of angio-genesis and their role in the development of VEGF inhibitors, Br JCancer 102 (2010), 8-18.
9. J. Dawes, K.J. Clemetson, G.O. Gogstad, J. Mc Gregor, P. Clezardin, C.V. Prowse and D.S. Pepper, A radioimmunoas-say for thrombospondin, used in a comparative study of thrombospondin, beta-thromboglobulin and platelet factor 4 inhealthy volunteers, Thromb Res 29 (1983), 569-581. (Pubitemid 13080949)
10. L.L. Leung and R.L. Nachman, Complex formation of platelet thrombospondin with fibrinogen, J Clin Invest70 (1982), 542-549. (Pubitemid 12054578)
11. L.L. Leung, Role of thrombospondin in platelet aggregation, J Clin Invest 74 (1984), 1764-1772. (Pubitemid 15214090)
12. M.A. Kowalska, L. Rauova and M. Poncz, Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombo-sis, Thromb Res 125 (2010), 292-296.
13. R.J. Sharpe, H.R. Byers, C.F. Scott, S.I. Bauer and T.E. Maione, Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4, J Natl Cancer Inst 82 (1990), 848-853. (Pubitemid 20149443)
14. S. Kazerounian, K.O. Yee and J. Lawler, Thrombospondins in cancer, Cell Mol Life Sci 65 (2008), 700-712.
15. A. Zaslavsky, K.H. Baek, R.C. Lynch, S. Short, J. Grillo, J. Folkman, J.E. Italiano, Jr. and S. Ryeom, Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis, Blood 115 (2010), 4605-4613.
16. R. Yabkowitz, P.J. Mansfield, V.M. Dixit and S.J. Suchard, Motility of human carcinoma cells in response to throm-bospondin: relationship to metastatic potential and throm-bospondin structural domains, Cancer Res 53 (1993), 378-387. (Pubitemid 23031853)
17. V. Abbasciano, D. Tassinari, S. Sartori, L. Trevisani, D. Ar-cudi, M.P. Bianchi and A. Liboni, Usefulness of coagulation markers in staging of gastric cancer, Cancer Detect Prev 19 (1995), 331-336.
18. V. Dymicka-Piekarska, A. Butkiewicz, H. Kemona, M. Gryko and M. Mantur, Does colorectal cancer clinical advancement and surgical treatment affect platelet factor 4 concentration, Pol Merkur Lekarski 17 (2004), 575-578. (Pubitemid 40091939)
19. T. Shaw, R.H. Smillie and D.G. Mac Phee, The role ofblood platelets in nucleoside metabolism: assay, cellular location and significance of thymidine phosphorylase in human blood, Mutat Res 200 (1988), 99-116.
20. J. Fujimoto, H. Sakaguchi, I. Aoki and T. Tamaya, The value of platelet-derived endothelial cell growth factor as a novel predictor of advancement of uterine cervical cancers, Cancer Res 60 (2000), 3662-3665. (Pubitemid 30482191)
21. W. Wynendaele, R. Derua, M.F. Hoylaerts, A. Pawinski, E. Waelkens, E.A. de Bruijn, R. Paridaens, W. Merlevede and A.T. van Oosterom, Vascular endothelial growth factor mea-sured in platelet poor plasma allows optimal separation be-tween cancer patients and volunteers: a key to study an angio-genic marker in vivo? Ann Oncol 10 (1999), 965-971. (Pubitemid 29424578)
22. R. Dittadi, S. Meo, F Fabris, G. Gasparini, D. Contri, M. Medici and M. Gion, Validation of blood collection proce-dures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartments, Int J Biol Markers 16 (2001), 87-96. (Pubitemid 32755125)
23. M.L. George, S.A. Eccles, M.G. Tutton, A.M. Abulafi and R.I. Swift, Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 6 (2000), 3147-3152. (Pubitemid 30637740)
24. E. Gunsilius, A. Petzer, G. Stockhammer, W. Nussbaumer, P. Schumacher, J. Clausen and G. Gastl, Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood, Oncology 58 (2000), 169-174. (Pubitemid 30113869)
25. H.M. Verheul, K. Hoekman, S. Luykx-de Bakker, C.A. Eekman, C.C. Folman, H.J. Broxterman and H.M. Pinedo, Platelet: transporter of vascular endothelial growth factor, Clin Cancer Res 3 (1997), 2187-2190. (Pubitemid 28133134)
26. C. Brostjan, A. Bayer, A. Zommer, A. Gornikiewicz, S. Roka, T. Benko, R. Yaghubian, R. Jakesz, G. Steger, M. Gnant, J. Friedl and A. Stift, Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy, Cancer 98 (2003), 2291-2301. (Pubitemid 37392435)
27. C. Brostjan, K. Gebhardt, B. Gruenberger, V. Steinrueck, H. Zommer, H. Freudenthaler, S. Roka and T. Gruenberger, Neoadjuvant treatment of colorectal cancer with bevacizum-ab: the perioperative angiogenic balance is sensitive to sys-temic thrombospondin-1 levels, Clin Cancer Res 14 (2008), 2065-2074. (Pubitemid 351551117)
28. K. Werther, S. Sorensen, I.J. Christensen and H.J. Nielsen, Circulating vascular endothelial growth factor six months af-ter primary surgery as a prognostic marker in patients with colorectal cancer, Acta Oncol 42 (2003), 837-845. (Pubitemid 38091184)
29. K. Fujisaki, K. Mitsuyama, A. Toyonaga, K. Matsuo and K. Tanikawa, Circulating vascular endothelial growth factor in patients with colorectal cancer, Am J Gastroenterol 93 (1998), 249-252. (Pubitemid 29063978)
30. G.L. Klement, T.T. Yip, F Cassiola, L. Kikuchi, D. Cervi, V. Podust, J.E. Italiano, E. Wheatley, A. Abou-Slaybi, E. Bender, N. Almog, M.W. Kieran and J. Folkman, Platelets actively sequester angiogenesis regulators, Blood 113 (2009), 2835-2842.
31. R. Ohkawa, Y. Hirowatari, K. Nakamura, S. Ohkubo, H. Ikeda, M. Okada, M. Tozuka, K. Nakahara and Y. Yatomi, Platelet release of beta-thromboglobulin and platelet factor 4 and sero-tonin in plasma samples, Clin Biochem 38 (2005), 1023-1026. (Pubitemid 41606799)
32. G. Bergseth, K.T. Lappegard, V. Videm and T.E. Mollnes, A novel enzyme immunoassay for plasma thrombospondin. Comparison with beta-thromboglobulin as platelet activation marker in vitro and in vivo, Thromb Res 99 (2000), 41-50. (Pubitemid 30440740)
33. P. Starlinger, H.P. Moll, A. Assinger, C. Nemeth, K. Hoet-zenecker, B. Gruenberger, T. Gruenberger, I. Kuehrer, S.F. Schoppmann, M. Gnant and C. Brostjan, Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes, J Thromb Haemost 8 (2010), 1809-1819.
34. P. Salven, A. Orpana and H. Joensuu, Leukocytes and platelets of patients with cancer contain high levels of vascular endothe-lial growth factor, Clin Cancer Res 5 (1999), 487-491. (Pubitemid 29131955)
35. H.M. Verheul and H.M. Pinedo, The importance of platelet counts and their contents in cancer, Clin Cancer Res 9 (2003), 3219-3221. (Pubitemid 37082715)
36. T. Wiesner, S. Bugl, F. Mayer, J.T. Hartmann and H.G. Kopp, Differential changes in platelet VEGF, Tsp, CXCL12, and CXCL4 in patients with metastatic cancer, Clin Exp Metastasis 27 (2010), 141-149.
37. F.J. Gonzalez, A. Rueda, I. Sevilla, L. Alonso, V. Villarreal, E. Torres and E. Alba, Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: relationship to platelet alpha-granule content andprimaryactivation, Int JBiol Markers19(2004), 221-228. (Pubitemid 39406244)
38. A.Z. Dudek and H. Mahaseth, Circulating angiogenic cy-tokines in patients with advanced non-small cell lung can-cer: correlation with treatment response and survival, Cancer Invest 23 (2005), 193-200. (Pubitemid 40770736)
39. K. Werther, I.J. Christensen and H.J. Nielsen, Prognostic im-pact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma, Br J Cancer 86 (2002), 417-423. (Pubitemid 34185127)
40. R.M. Roumen, G.D. Slooter, FA. Croiset van Uchelen and L.V. Huib, Preoperative serum vascular endothelial growth factor is not a marker for subsequent recurrence during long-term follow-up of colorectal cancer patients, Dis Colon Rec-tum 48 (2005), 1070-1075. (Pubitemid 40884199)